Abstract
This report reviews the medicinal agents that have been linked to human cancer, with emphasis on recent evidence implicating estrogenic compounds such as DES, menopausal estrogens, and oral contraceptives. Attention is also given to drugs that have fallen under suspicion and requires further epidemiologic evaluation. The detection of drug-cancer associations not only influences clinical and public health practice, but may also provide insights into mechanisms of carcinogenesis. The clinician contributes to the prevention of drug-induced cancer by being alert to iatrogenic hazards and cooperating in epidemiologic investigations, by weighing risks versus benefits in individual cases, and by discussing with patients the rationale and risks of proposed forms of therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
